Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.
Lee
Jin
J
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D008297:Male; D010976:Platelet Count; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D013920:Thrombocythemia, Essential / Q000188:drug therapy*; D016896:Treatment Outcome; D000077337:Vorinostat
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D000077337:Vorinostat